According to the Human Protein Atlas database, high ARHGEF3 expression is favorable for patient survival and potentially a prognostic marker for renal cancer, endometrial cancer, and head and neck cancer, and others. This evidence concerns the gene ARHGEF3 and endometrial cancer.